BioSpace News Archive

In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis’ headquarters, located at 8, rue de la Croix Jarry, 4th floor, 75013 Paris, France behind closed doors, i.e. without the physical presence of the shareholders.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace, is pleased to report that the Company has developed a new version of its THC Breath Analyzer (“THCBA”) and is preparing for additional testing with the device.

As a result of the Global Pandemic of Covid-19, Obtain Medical (the sister company of the internationally respected Solve Distribution) has partnered with Olvad Holdings to respond and assist in giving their combined international support to this problem.

MilliporeSigma, a leader in genome editing, announced that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the United States.

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time. The discussion will be available to all interested parties through a live audiocast accessible via the Investor Relations section of the LivaNova website at www.livanova.com . Listeners s

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that cGMP Validation, the company’s GMP consultant, is conducting its final audit of the manufacturing facility in Thailand where PharmaCyte’s clinical trial product was produced by PharmaCyte’s partne

Today, Vigilant Ops, an innovator in medical device cybersecurity, announced the immediate availability of InSight Platform V1, enabling medical device manufacturers to begin automatically generating, updating, and monitoring device software bills of materials.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has appointed Dr. Mark Swaim to the board of directors of its wholly-owned subsidiary, Blife Therapeutics Inc.

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Tiburio Therapeutics Inc., a clinical stage company developing therapies for rare endocrine diseases, today published new data from a preclinical study in the Journal of the Endocrine Society demonstrating that its lead clinical asset, TBR-760, a dopamine somatostatin chimeric compound, arrests aggressive non-functioning pituitary adenoma (NFPA) growth in a mouse model. The pre-clinical data indicate that TBR-760 completely arrested tumor gr